Modern approaches to the treatment of type 2 diabetes mellitus
https://doi.org/10.21518/2079-701X-2018-4-17-19
Abstract
Combination of lifestyle changes and drug therapy is necessary to achieve and maintain optimal glycemic control in type 2 diabetes. Currently, various hypoglycemic drugs of both tableted and injectable forms with different mechanisms of action are used. The article presents data on modern approaches to the selection of glucose reducing drugs for type 2 diabetes mellitus.
About the Authors
T. V. Morgunova
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
V. V. Fadeev
Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Standards of specialized diabetes care. Edited by Dedova II, Shestakova MV. (8th edition). Sakharny Diabet, 2017, 20(1S): 1-112. doi: 10.14341/DM20171S8.
2. Marín-Peñalver JJ, Martín-Timón I, SevillanoCollantes C, Del Cañizo-Gómez FJ. Update on the treatment of type 2 diabetes mellitus. World J Diabetes, 2016 Sep 15, 7(17): 354-95. doi: 10.4239/wjd.v7.i17.354. Review.
3. del Cañizo-Gómez FJ, Moreira-Andrés MN. Cardiovascular risk factors in patients with type 2 diabetes. Do we follow the guidelines? Diabetes Res Clin Pract, 2004, 65: 125-133.
4. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38(1): 140–49.
5. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract, 2016, 22(1): 84–113.
6. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006, 355(23): 2427–43.
7. Seck T, Nauck M, Sheng D et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract, 2010, 64(5): 562–76.
8. Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared to glipizide over 2 years when used in combination with metformin. Diabetes Obes Metab, 2014, 16(12): 1239–46.
9. Del Prato S, Fleck P, Wilson C, Chaudhari P. Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus. Diabetes Obes Metab, 2016, 18(6): 623–27.
10. Leiter LA, Yoon KH, Arias P et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care, 2015, 38(3): 355–64.
11. Ridderstråle M, Andersen KR, Zeller C et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet. Diabetes Endocrinol, 2014, 2(9): 691–700.
12. Nauck MA, Del Prato S, Durán-García S et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab, 2014, 16(11): 1111–20.
Review
For citations:
Morgunova TV, Fadeev VV. Modern approaches to the treatment of type 2 diabetes mellitus. Meditsinskiy sovet = Medical Council. 2018;(4):17-19. (In Russ.) https://doi.org/10.21518/2079-701X-2018-4-17-19
Views: 868
Email this article 